logo-loader
viewPolarean Imaging PLC

Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas MRI. By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

Quick facts: Polarean Imaging PLC

Price: 38 GBX

AIM:POLX
Market: AIM
Market Cap: £61.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging welcomes new strategic investor as it raises £8.4mln in new...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott after conditionally raising £8.4mln (US$10.7mln) before expenses. He says the extra cash will help to strengthen its balance sheet while it prepares for the new drug application (NDA) for its...

on 18/3/20

2 min read